Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Anti-Myeloma Drug, Perifosine, May Also Work Against Colon Cancer

Home/Uncategorized/Anti-Myeloma Drug, Perifosine, May Also Work Against Colon Cancer

Anti-Myeloma Drug, Perifosine, May Also Work Against Colon Cancer

Interesting news I wanted to share about one of several new anti-myeloma therapy agents, perifosine.  Currently in Phase 3 trials in combination with Velcade, perifosine apparently has anti-cancer properties which go far beyond multiple myeloma: 

Aeterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Trial with Perifosine in Colorectal Cancer

The multicenter X-PECT (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) Phase 3 study involving approximately 430 patients, is a double-blind, placebo-controlled study comparing the combination of perifosine and capecitabine (Xeloda(R)) with single-agent capecitabine (Xeloda(R)). Patients in this study have been intensively pre-treated and have failed all available treatment options except capecitabine (Xeloda(R)). Overall survival will be analyzed as the primary efficacy endpoint, with secondary endpoints including overall response rate (complete + partial responses), progression-free survival and safety.

Last April, Aeterna Zentaris had also received positive Scientific Advice from the EMA for the ongoing Phase 3 trial in multiple myeloma with perifosine, being conducted by Keryx in the United States. The trial is a double-blind, placebo-controlled study of perifosine combined with bortezomib (Velcade(R)) in bortezomib pre-treated patients. Progression-free survival is the primary efficacy endpoint in this trial, which will include follow-up for overall survival.

Read the entire article, including additional multiple myeloma related info by going to
Feel good and keep smiling!  Pat